Wyeth Emphasizes Effexor XR’s Second-Line Bona Fides
This article was originally published in The Pink Sheet Daily
Executive Summary
The company responds to a study suggesting its venlafaxine antidepressant had not previously shown second-line efficacy.
You may also be interested in...
Antidepressants Produce Similar Remission Rates, NIMH Study Finds
Wellbutrin SR, Zoloft and Effexor XR all provide “reasonable second step” for treatment-resistant depression, STAR*D trial suggests.
Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says
Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.
Nebivolol Approval Could Come In Mid-2007, Forest Says
The firm is conducting small studies of short duration after meeting with FDA regarding a May 2005 “approvable” letter.